This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Bristol's Immunotherapy Duo Doubles Survival in Melanoma Patients

Stocks in this article: BMY MRK

CHICAGO ( TheStreet) -- Combination therapy involving two immunotherapy drugs from Bristol-Myers Squibb (BMY) extended median overall survival to almost three and half years in patients with advanced melanoma, according to updated results from a phase I study described as "remarkable" by investigators at the American Society of Clinical Oncology (ASCO) annual meeting. 

The two Bristol drugs -- the still-experimental nivolumab and the approved Yervoy -- work by blocking "checkpoints" on T-cells which prevent the immune system from recognizing and killing cancer cells. Similar checkpoint inhibitors, or anti-PD1 and anti-PDL-1 drugs, are being developed by Merck (MRK) and AstraZeneca (AZN), among other companies. Collectively, the development and approval of new classes of cancer immunotherapies have the potential to generate tens of billions of dollars in new revenue for these companies. 

In the study, 94 melanoma patients no longer responding to prior therapies -- half with very advanced disease -- all received combinations of nivolumab and Yervoy at different doses. Long-term follow-up results from 53 patients enrolled in the first four dosing cohorts were announced Monday. Overall 22 of the 53 patients (41%) responded to the nivolumab-Yervoy combination therapy. Across all doses, the one- and two-year survival rates were 85% and 79%, respectively, with a median overall survival of 39.7 months.

"Just a few years ago, median survival for patients diagnosed with advanced melanoma was as little as a year or less, and only approximately 20-25% survived two years, so it's truly remarkable that we're seeing a median survival over three years in this trial," said Dr. Mario Sznol from Yale's School of Medicine and an investigator in the study, in a statement.

Sznol notes that median survival in melanoma is about 16-18 months when cancer immunotherapies are used alone, so the combination of two of these new drugs doubled survival. He cautions, however, that the phase I study was small so encouraging results need to be confirmed in a larger, randomized phase III study.

Bristol is conducting a 900-patient, phase III study in melanoma comparing nivolumab monotherapy, the nivolumab-Yervoy combination and Yervoy monotherapy. At the nivolumab-Yervoy dose being used in the phase III study, the one- and two-year overall survival rates were 94% and 88%, respectively, in the phase I study. 

Also today, Merck announced results from a study of its checkpoint inhibitor MK-3475 used as monotherapy in melanoma patients. Overall, 34% of patients experienced a tumor response with a one-year survival rate of 69%. In a subgroup of patients not previously treated with Yervoy, the response rate to MK-3475 was 40% and the one-year survival rate was 74%.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs